Histaprodifens
J ournal of Medicinal Chemistry, 2000, Vol. 43, No. 6 1083
(23) Kramer, K.; Elz, S.; Pertz, H. H.; Schunack, W. NR-Alkylated
Derivatives of 2-Phenylhistamine: Synthesis and In-Vitro Activ-
ity of Potent Histamine H1-Receptor Agonists. Bioorg. Med.
Chem. Lett. 1998, 8, 2583-2588.
(24) Detert, H.; Leschke, C.; To¨gel, W.; Seifert, R.; Schunack, W.
2-Alkyl-Substituted Histamines and Hydroxyethylimidazoles
with G-Protein-Stimulatory Activity. Eur. J . Med. Chem. 1996,
31, 397-405.
(25) Nu¨rnberg, B.; To¨gel, W.; Krause, G.; Storm, R.; Breitweg-
Lehmann, E.; Schunack, W. Non-Peptide G-Protein Activators
as Promising Tools in Cell Biology and Potential Drug Leads.
Eur. J . Med. Chem. 1999, 34, 5-30.
(26) Handley, D. A.; Hong, Y.; Bakale, R.; Senanayake, C. Norastemi-
zole. Drugs Future 1998, 23, 966-969.
Refer en ces
(1) Kramer, K.; Detert, H.; Leschke, C.; Elz, S.; Schunack, W. 2-(3,3-
Diphenylpropyl)histamine: A Lead for Highly Potent H1-Recep-
tor Agonists. XXVIth Meeting of the European Histamine
Research Society, Sevilla, Spain, May 14-17, 1997, Abstract No.
28.
(2) Kramer, K.; Detert, H.; Elz, S.; Pertz, H.; Schunack, W. A New
Class of Selective and Highly Potent Histamine H1-Receptor
Agonists: NR-Substituted Derivatives of Histaprodifen. XXVIIth
Meeting of the European Histamine Research Society, Lo´dz,
Poland, May 20-23, 1998, Abstract No. 38.
(3) Elz, S.; Kramer, K.; Pertz, H.; Schunack, W. Methylhistaprodifen
and Congeners: Highly Potent and Selective Histamine H1-
Receptor Agonists. XIIIth International Congress of Pharmacol-
ogy, Munich, Germany, J uly 26-31, 1998; Naunyn-Schmiede-
berg’s Arch. Pharmacol. 1998, 358 (Suppl. 2), R762.
(4) Tuomisto, L.; Tacke, U. Is Histamine an Anticonvulsive Inhibi-
tory Transmitter? Neuropharmacology 1986, 25, 955-958.
(5) Yokoyama, H.; Onodera, K.; Maeyama, K.; Yanai, K.; Iinuma,
K.; Tuomisto, L.; Watanabe, T. Histamine Levels and Clonic
Convulsions of Electrically-Induced Seizure in Mice: The Effects
of R-Fluoromethylhistidine and Metoprine. Naunyn-Schmiede-
berg’s Arch. Pharmacol. 1992, 346, 40-45.
(6) Oishi, R.; Adachi, N.; Saeki, K. N-R-Methylhistamine Inhibits
Intestinal Transit in Mice by Central Histamine H1 Receptor
Activation. Eur. J . Pharmacol. 1993, 237, 155-159.
(7) Toda, N. Mechanism of Histamine Actions in Human Coronary
Arteries. Circ. Res. 1987, 61, 280-286.
(8) Matsanuyama, K.; Yasue, H.; Okumura, K.; Matsuyama, K.;
Ogawa, H.; Morikami, Y.; Inotsume, N.; Nakano, M. Effects of
H1 Receptor Stimulation on Coronary Arterial Diameter and
Coronary Hemodynamics in Humans. Circulation 1990, 81, 65-
71.
(9) Okumura, K.; Yasue, H.; Matsuyama, K.; Morikami, Y.; Ogawa,
H.; Obata, K. Effects of H1 Receptor Stimulation on Coronary
Artery Diameter in Patients with Varient Angina: Comparison
with Effect of Acetylcholine. J . Am. Coll. Cardiol. 1991, 17, 338-
345.
(10) Monti, J . M.; J antos, H.; Leschke, C.; Elz, S.; Schunack, W. The
Selective Histamine H1-Receptor Agonist 2-(3-Trifluorometh-
ylphenyl)histamine Increases Waking in the Rat. Eur. Neurop-
sychopharmacol. 1994, 4, 459-462.
(11) Durant, G. J .; Duncan, W. A. M.; Ganellin, C. R.; Parson M. E.;
Blakemore, R. C.; Rasmussen, A. C. Impromidine (SK&F 92676)
is a Very Potent and Specific Agonist for Histamine H2 Recep-
tors. Nature (London) 1978, 276, 403-405.
(12) Buschauer, A. Synthesis and In Vitro Pharmacology of Arpro-
midine and Related Phenyl(pyridylalkyl)guanidines, a Potential
New Class of Positive Inotropic Drugs. J . Med. Chem. 1989, 32,
1963-1970.
(13) Arrang, J .-M.; Garbarg, M.; Lancelot, J .-C.; Lecomte, J .-M.;
Pollard, H.; Robba, M.; Schunack, W.; Schwartz, J .-C. Highly
Potent and Selective Ligands for Histamine H3-Receptors.
Nature (London) 1987, 327, 117-123.
(14) Garbarg, M.; Arrang, J .-M.; Rouleau, A.; Ligneau, X.; Trung
Tuong, M. D.; Schwartz, J .-C.; Ganellin, C. R. S-[2-(4-Imidazolyl)-
ethyl]isothiourea, a Highly Specific and Potent Histamine H3
Receptor Agonist. J . Pharmacol. Exp. Ther. 1992, 263, 304-
310.
(15) Hill, S. J .; Ganellin, C. R.; Timmerman, H.; Schwartz, J .-C.;
Shankley, N. P.; Young, J . M.; Schunack, W.; Levi, R.; Haas, H.
L. International Union of Pharmacology. XIII. Classification of
Histamine Receptors. Pharmacol. Rev. 1997, 49, 253-278.
(16) Zingel, V.; Leschke, C.; Schunack, W. Developments in Hista-
mine H1-Receptor Agonists. Prog. Drug Res. 1995, 44, 49-
85.
(27) Unger, V. M.; Hargrave, P. A.; Baldwin, J . M.; Schertler, G. F.
X. Arrangement of Rhodopsin Transmembrane R-Helices. Nature
(London) 1997, 389, 203-206.
(28) Dziuron, P.; Schunack, W. A New Synthesis of Imidazole
Derivatives. Arch. Pharm. (Weinheim, Ger.) 1973, 306, 347-350.
(29) Take, K.; Okumura, K.; Tsubaki, K.; Terai, T.; Shiokawa, Y.
Agents for the Treatment of Overactive Detrusor. IV. Synthesis
and Structure-Activity Relationships of Cyclic Analogues of
Terodiline. Chem. Pharm. Bull. 1993, 41, 507-515.
(30) Vorbru¨ggen, H. Reactive Isocyanates. I. Direct Introduction of
Nitrile Groups into Unsaturated Systems. Simple Conversion
of Carboxylic Acids into Nitriles. Tetrahedron Lett. 1968, 13,
1631-1634.
(31) Reppe, W. IV. Ethynylation. J ustus Liebigs Ann. Chem. 1955,
596, 38-79.
(32) Zingel, V.; Elz, S.; Schunack, W. Histamine Analogues. XXXIII.
2-Phenylhistamines with High Histamine H1-Agonistic Activity.
Eur. J . Med. Chem. 1990, 25, 673-680.
(33) Kenakin, T. P.; Cook, D. A. N,N-Diethyl-2-(1-pyridyl)ethylamine,
a Partial Agonist for Histamine Receptors in Guinea Pig Ileum.
Can. J . Physiol. Pharmacol. 1980, 58, 1307-1310.
(34) Arunlakshana, O.; Schild, H. O. Some Quantitative Uses of Drug
Antagonists. Br. J . Pharmacol. Chemother. 1959, 14, 48-58.
(35) Marano, M.; Kaumann, A. J . On the Statistics of Drug-Receptor
Constants for Partial Agonists. J . Pharmacol. Exp. Ther. 1976,
198, 518-525.
(36) Kaumann, A. J .; Marano, M. On Equilibrium Dissociation
Constants for Complexes of Drug-Receptor Subtypes. Selective
and Non-Selective Interactions of Partial Agonists with Two
Plausible â-Adrenoceptor Subtypes Mediating Positive Chrono-
tropic Effects of (-)-Isoprenaline in Kitten Atria. Naunyn-
Schmiedeberg’s Arch. Pharmacol. 1982, 318, 192-201.
(37) Dodel, R.; Borchard, U. The Affinity of Antihistamines to
Peripheral Histamine H1-Receptors. Agents Actions 1992, 37,
C410-C413.
(38) Van der Voorde, J .; Leusen, I. Vascular Endothelium and the
Relaxation Effect of Histamine on Aorta of the Rat. Arch. Int.
Pharmacodyn. Ther. 1982, 256, 329-330.
(39) Van der Voorde, J .; Leusen, I. Role of the Endothelium in the
Vasodilator Response of Rat Thoracic Aorta to Histamine. Eur.
J . Pharmacol. 1983, 87, 113-120.
(40) Carrier, G. O.; White, R. E.; Kirby, M. L. Histamine-Induced
Relaxation of Rat Aorta. Importance of H1 Receptor and Vascular
Endothelium. Blood Vessels 1984, 21, 180-183.
(41) Ohta, K.; Hayashi, H.; Mizuguchi, H.; Kagamiyama, H.; Fujim-
oto, K.; Fukui, H. Site-Directed Mutagenesis of the Histamine
H1 Receptor: Roles of Aspartic Acid107, Asparagine198 and
Threonine194. Biochem. Biophys. Res. Commun. 1994, 203,
1096-1101.
(42) Nonaka, H.; Otaki, S.; Oshima, E.; Kono, M.; Kase, H.; Ohta,
K.; Fukui, H.; Ichimura, M. Unique Binding Pocket for KW-4679
in the Histamine H1 Receptor. Eur. J . Pharmacol. 1998, 345,
111-117.
(43) Ter Laak, A. M.; Timmerman, H.; Leurs, R.; Nederkoorn, P. H.
J .; Smit, M. J .; Donne´-Op den Kelder, G. M. Modeling and
Mutation Studies on the Histamine H1 Receptor Agonist Binding
Site Reveal Different Binding Modes for H1-Agonists: Asp116
(TM3) Has a Constitutive Role in Receptor Stimulation. J .
Comput. Aided Mol. Des. 1995, 9, 319-330.
(44) Leurs, R.; Smit, M. J .; Tensen, C. P.; ter Laak, A. M.; Timmer-
man, H. Lys200 Located in the Fifth Transmembrane Domain
of the Histamine H1 Receptor Interacts with Histamine but not
with All H1 Agonists. Biochem. Biophys. Res. Commun. 1994,
201, 295-301.
(17) Durant, G. J .; Ganellin, C. R.; Parsons, M. E. Chemical Dif-
ferentiation of Histamine H1- and H2-Receptor Agonists. J . Med.
Chem. 1975, 18, 905-909.
(18) Hepp, M.; Dziuron, P.; Schunack, W. Structure-Activity Rela-
tionships of Histamine Analogues. XIX. 2-Substituted Hista-
mines with Selective H1-Agonistic Activity. Arch. Pharm. (Wein-
heim, Ger.) 1979, 312, 637-639.
(19) Dziuron, P.; Schunack, W. Structure-Activity Relationships of
Histamine Analogues. VIII. Synthesis and Activity of 2-Substi-
tuted Histamines. Eur. J . Med. Chem. Chim. Ther. 1975, 10,
129-133.
(45) Moguilevsky, N.; Varsolana, F.; Guillaume, J .-P.; Noyer, M.;
Gillard, M.; Daliers, J .; Henichart, J .-P.; Bollen, A. Pharmaco-
logical and Functional Characterisation of the Wild-Type and
Site-Directed Mutants of the Human H1 Histamine Receptor
Stably Expressed in CHO Cells. J . Recept. Signal Transduction
Res. 1995, 15, 91-102.
(46) Elz, S.; Kramer, K.; Leschke, C.; Schunack, W. Ring-Substituted
Histaprodifen Analogues as Partial Agonists for Histamine H1
Receptors: Synthesis and Structure-Activity Relationships.
Eur. J . Med. Chem. 2000, 35, 1-12.
(20) For nomenclature see: Black, J . W.; Ganellin, C. R. Naming
Substituted Histamines. Experientia 1974, 30, 111-113.
(21) Leschke, C.; Elz, S.; Garbarg, M.; Schunack, W. Synthesis and
Histamine H1 Receptor Agonist Activitiy of a Series of 2-Phen-
ylhistamines, 2-Heteroarylhistamines, and Analogues. J . Med.
Chem. 1995, 38, 1287-1294.
(22) Hepp, M.; Schunack, W. Structure-Activity Relationships of
Histamine Analogues. XXI. Synthesis and Pharmacology of NR-
Substituted Histamines. Arch. Pharm. (Weinheim, Ger.) 1980,
313, 756-762.